NanoPass Technologies Grants a Commercial License to Janssen Pharmaceuticals, Inc., for use of its MicronJet Device
NES ZIONA, Israel, November 29, 2012 /PRNewswire/ –
NanoPass Technologies Ltd. (“NanoPass”), a pioneer in intradermal delivery solutions
for vaccines, announced today that it has entered into a license agreement for
MicronJet(R), its microneedle delivery device, with Janssen Pharmaceuticals, Inc. (JPI)
for multiple vaccine fields.
The license agreement will provide Janssen with an exclusive license to use the device
in its seasonal influenza programs and options for additional vaccine fields. Financial
terms were not disclosed.
Yotam Levin, Chief Executive Officer of NanoPass, said, “We are delighted to enter
into this license agreement with Janssen, a leading pharmaceutical company. We see a
significant opportunity for improving immunogenicity and/or reducing the dose of
vaccination, by combining our device approach with Crucell’s vaccines. The agreement with
Janssen is a significant milestone towards full market acceptance.”
Dr. Richard Kenney, Chief Medical Officer of Crucell, an affiliate of Janssen, said,
“Combining the NanoPass MicronJet600 device with Crucell’s virosomal influenza vaccine
technology has the potential to change the qualitative immune response to provide benefits
in ways that cannot be predicted. Effective vaccination in the elderly is urgently needed;
we hope this is the first step toward an improved vaccine.”
About NanoPass Technologies Ltd.
NanoPass has concluded multiple seasonal flu studies as well as the world’s first
intradermal H1N1 pandemic flu vaccine study, demonstrating equivalent or superior
immunogenicity to standard intramuscular delivery using only 20% of the dose [i,ii,iii].
The company is backed by prominent investors including IHCV, Ofer Hi-Tech, DPartners, WFD
Ventures and Elcam Medical.
MicronJet is a microneedle-based device for ID delivery of vaccines and drugs,
enabling consistent, nearly painless and simple delivery of therapeutics directly into the
skin. MicronJet has proven efficacy and safety in multiple applications including flu
vaccines and insulin. MicronJet is approved for marketing in various territories including
the USA, for use by health care professionals for intradermal delivery (see label).
i Hung IFN, Levin Y, To KK. Quantitative and qualitative analysis of antibody response
after dose sparing intradermal 2009 H1N1 vaccination. Vaccine. 2012;30(17):2707-8.
ii Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M et al. Safety and efficacy of a
novel microneedle device for dose sparing intradermal influenza vaccination in healthy
adults. Vaccine. 2009;27(3):454-9.
iii. Hung IFN, Levin Y, To KWW, Chan KH, Zhang AJ, Li P, Li C, Xu T, Wong TY and Yuen
KY. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced
immunogenicity of the 2009 H1N1 strain. Vaccine. In Press.2012.
Contact: Yotam Levin, CEO: +972-523-392727 firstname.lastname@example.org
SOURCE NanoPass Technologies LTD.